Neonatal neurobehavior effects following buprenorphine versus methadone exposure
Authors:
Open Access
Abstract
Aim: To determine the effects of in utero exposure to methadone or buprenorphine on infant neurobehavior.Design: Three sites from the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study, a double‐blind, double‐dummy, randomized clinical trial participated in this substudy.Setting: Medical Centers that provided comprehensive maternal care to opioid‐dependent pregnant women in Baltimore, MD, Providence, RI and Vienna, Austria.Participants: Thirty‐nine full‐term infants.Measurements: The Neonatal Intensive Care Unit (NICU) Network Neurobehavioral Scale (NNNS) was administered to a subgroup of infants on postpartum days 3, 5, 7, 10, 14–15 and 28–30.Findings: While neurobehavior improved for both medication conditions over time, infants exposed in utero to buprenorphine exhibited fewer stress‐abstinence signs (P < 0.001), were less excitable (P < 0.001) and less over‐aroused (P < 0.01), exhibited less hypertonia (P < 0.007), had better self‐regulation (P < 0.04) and required less handling (P < 0.001) to maintain a quiet alert state relative to in utero methadone‐exposed infants. Infants who were older when they began morphine treatment for withdrawal had higher self‐regulation scores (P < 0.01), and demonstrated the least amount of excitability (P < 0.02) and hypertonia (P < 0.02) on average. Quality of movement was correlated negatively with peak NAS score (P < 0.01), number of days treated with morphine for NAS (P < 0.01) and total amount of morphine received (P < 0.03). Excitability scores were related positively to total morphine dose (P < 0.03).Conclusion: While neurobehavior improves during the first month of postnatal life for in utero agonist medication‐exposed neonates, buprenorphine exposure results in superior neurobehavioral scores and less severe withdrawal than does methadone exposure.Keywords
This publication has 27 references indexed in Scilit:
- Fetal neurobehavioral effects of exposure to methadone or buprenorphineNeurotoxicology and Teratology, 2011
- Neonatal Abstinence Syndrome after Methadone or Buprenorphine ExposureNew England Journal of Medicine, 2010
- Infant Neurobehavior Following Prenatal Exposure to Methadone or Buprenorphine: Results From the Neonatal Intensive Care Unit Network Neurobehavioral ScaleSubstance Use & Misuse, 2010
- Neonatal Neurobehavior Predicts Medical and Behavioral OutcomePediatrics, 2010
- Prenatal Methadone Exposure and Neonatal Neurobehavioral FunctioningPediatric Research, 2009
- Maternal depression and neurobehavior in newborns prenatally exposed to methamphetamineNeurotoxicology and Teratology, 2009
- Maternal Smoking during Pregnancy and Newborn Neurobehavior: Effects at 10 to 27 DaysThe Journal of Pediatrics, 2009
- Treatment of opioid-dependent pregnant women: Clinical and research issuesJournal of Substance Abuse Treatment, 2008
- Neurobehavioral effects of treatment for opiate withdrawal: Figure 1Archives of Disease in Childhood - Fetal and Neonatal Edition, 2004
- STATE ORGANIZATION IN NEONATES: DEVELOPMENTAL INCONSISTENCY INDICATES RISK FOR DEVELOPMENTAL DYSFUNCTIONNeuropediatrics, 1981